Subcutaneous octreotide therapy for malignant pleural effusion after pleurodesis with talc powder: A placebo-controlled, triple-blind, randomized trial

Phase 3

• Conditions: Malignant pleural effusion.; Malignant pleural effusion; J91.0

• Registration Number: IRCT20210915052492N1
• Lead Sponsor: Tehran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 1 November 2021

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 46

Inclusion Criteria

Patients with cancer and malignant pleural effusion
Chest tube discharge>150 cc/day
Estimated survival>6 months

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The amount of discharge from the chest tube before and after pleurodesis. Timepoint: Before and after intervention. Method of measurement: Chest tube.

Secondary Outcome Measures

Name	Time	Method
Hospital stay. Timepoint: After intervention. Method of measurement: Days.